Posts
A human papillomavirus infection can be transmitted to different
parts of the body, but the most common way of transmission is through sexual
intercourse. This means that you may pass this virus to your partner, and they
will carry it to another part of their body where s/he may have an outbreak.
However, there are cases where the virus is not transmitted, or only the
carrier of the virus develops an infection and s/he does not transmit it to
another person. This is also known as secondary infection. Often, HPV infection
doesn’t cause any noticeable symptoms or health problems.
Market Dynamics
High prevalence of cancer is expected to propel growth of the human
papillomavirus (HPV) infection vaccines market. For instance, according to
the American Cancer Society, in 2019, there will be an estimated 1,762,450 new
cancer cases diagnosed and 606,880 cancer deaths in the U.S. Moreover, launch
of immunization programs for human papillomavirus is also expected to aid in
growth of the market. For instance, in December 2019, Cote d’ Ivoire and
Liberia launched the National Immunization Program (NIP) for the
Human-Papillomavirus.
Launch of human papillomavirus tests is expected to offer
lucrative growth opportunities for players in the human papillomavirus (HPV)
infection vaccines market. For instance, in April 2020, F. Hoffmann-La Roche AG
received the U.S. Food and Drug Administration approval for its cobas HPV test
for use on the fully automated, high-throughput cobas 6800/8800 Systems.
Moreover, investment in screening the presence of human papilloma virus is also
expected to aid in growth of the market. For instance, in June 2020, National
Cancer Institute granted US$ 3.1 million to a researcher at Fox Chase Cancer
Center (Pennsylvania, U.S.) for a study evaluating a method that allows Asian
American women to collect their own samples, which can then be tested for the
presence of the human papilloma virus (HPV).
Reluctance to vaccination in several developed and emerging
economies is expected to hinder growth of the human papillomavirus (HPV)
infection vaccines market.
Competitive Analysis
Major players operating in the human papillomavirus (HPV)
infection vaccines market include, Merck & Co., Inc. and GlaxoSmithKline
plc. The companies having the candidate for HPV vaccines are Shanghai Bovax
Biotechnology Co., Ltd., Profectus BioSciences, Inc., 2A Pharma AB and ISA
Pharmaceuticals.
No comments:
Post a Comment